Tranylcypromine

A monoamine oxidase inhibitor used as an antidepressant

Tranylcypromine
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Tranylcypromine is a monoamine oxidase inhibitor (MAOI) used as an antidepressant. It is primarily used to treat major depressive disorder and is known for its effectiveness in patients who do not respond to other treatments.

Pharmacology

Tranylcypromine works by inhibiting the activity of the enzyme monoamine oxidase, which is responsible for breaking down neurotransmitters such as serotonin, norepinephrine, and dopamine. By inhibiting this enzyme, tranylcypromine increases the levels of these neurotransmitters in the brain, which can help alleviate symptoms of depression.

Medical uses

Tranylcypromine is used in the treatment of major depressive disorder, particularly in cases where other antidepressants have failed. It is also sometimes used in the treatment of anxiety disorders and panic disorder.

Side effects

Common side effects of tranylcypromine include dizziness, dry mouth, insomnia, and headache. More serious side effects can include hypertensive crisis, especially when taken with certain foods or other medications that interact with MAOIs.

Interactions

Tranylcypromine can interact with a variety of substances, including certain foods and medications. Foods high in tyramine, such as aged cheeses and cured meats, should be avoided as they can cause a dangerous increase in blood pressure. It is also important to avoid other medications that can interact with MAOIs, such as certain antidepressants, sympathomimetics, and opioids.

History

Tranylcypromine was first introduced in the 1960s as an antidepressant. It was one of the first MAOIs to be used clinically and has been used in the treatment of depression for several decades.

Synthesis

The synthesis of tranylcypromine involves the cyclization of phenylalanine derivatives. The process results in the formation of a cyclopropylamine structure, which is crucial for its activity as an MAOI.

Related pages

• Monoamine oxidase inhibitor
• Major depressive disorder
• Antidepressant